Osimertinib
About
Therapy type: Targeted therapy
Therapy strategy: EGFR inhibition
Mappings
NCI Thesaurus: Osimertinib (coding:ncit:C116377)
RxNorm: osimertinib (coding:rxcui:1721560, coding:omop:35605522)
SNOMED: Osimertinib (coding:sctid:716032009, coding:omop:37396277)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (3) HC (3) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Osimertinib | |
| FDA (3) HC (3) | EGFR p.L858R | Non-Small Cell Lung Cancer | Osimertinib | |
| FDA (1) HC (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Cisplatin, Osimertinib, Pemetrexed | |
| FDA (1) HC (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Carboplatin, Osimertinib, Pemetrexed | |
| FDA (1) HC (1) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Carboplatin, Osimertinib, Pemetrexed | |
| FDA (1) HC (1) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Cisplatin, Osimertinib, Pemetrexed | |
| FDA (1) HC (1) | EGFR p.T790M | Non-Small Cell Lung Cancer | Osimertinib |